Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2026 | GLP-1 therapy and hormone receptor–positive breast cancer risk and survival: a real-world analysis

Zunairah Shah • 30 May 2026
ASCO 2026
Breast Cancer

Zunairah Shah, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, discusses findings from a large real-world analysis evaluating GLP-1 receptor agonist therapy and hormone receptor-positive breast cancer risk. Dr Shah highlights the reduced incidence of hormone receptor-positive breast cancer observed in women receiving GLP-1 therapy and discusses ongoing efforts to better understand the underlying biological mechanisms. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Zunairah Shah

Real-world brain metastasis outcomes with T-DXd vs tucatinib-based therapy in second-line HER2+ mBC
1:24
Real-world brain metastasis outcomes with T-DXd vs tucatinib-based therapy in second-line HER2+ mBC
Zunairah Shah • 30 May 2026
Racial disparities in TNBC outcomes with neoadjuvant chemoimmunotherapy
0:52
Racial disparities in TNBC outcomes with neoadjuvant chemoimmunotherapy
Zunairah Shah • 1 Jun 2025
Real-world racial disparities in outcomes with HER2-directed ADCs in mBC
1:47
Real-world racial disparities in outcomes with HER2-directed ADCs in mBC
Zunairah Shah • 1 Jun 2025

Related Videos

Radiation response as a biomarker for adjuvant breast cancer therapy
1:56
Radiation response as a biomarker for adjuvant breast cancer therapy
Corey Speers • 1 Jun 2026
Expanding the clinical use of multimodal AI in breast cancer care
1:38
Expanding the clinical use of multimodal AI in breast cancer care
Corey Speers • 1 Jun 2026
MMAI model validation for chemotherapy benefit prediction in breast cancer
1:58
MMAI model validation for chemotherapy benefit prediction in breast cancer
Corey Speers • 1 Jun 2026
Real-world brain metastasis outcomes with T-DXd vs tucatinib-based therapy in second-line HER2+ mBC
1:24
Real-world brain metastasis outcomes with T-DXd vs tucatinib-based therapy in second-line HER2+ mBC
Zunairah Shah • 30 May 2026
The content of VJOncology is intended for healthcare professionals